SRM-2015-02_E
(DCO 3277)Confidential Page 1 of 46POST-APPROVAL STUDY of TRANSCAROTID ARTERY 
REVASCULARIZATION in PATIENTS with SIGNIFICANT CAROTID 
ARTERY DISEASE. 
 The ROADSTER 2 Study 
Clinical Protocol SRM â€“2015 â€“02
Version E
Version Date February 10, 2017
Sponsored by: 
Silk Road Medical, Inc. 
735 North Pastoria Avenue 
Sunnyvale, CA  94085 
United States of America 
Phone: +1 (408) 720-9002 
Fax: +1 (408) 720 9013 1&7
  
SRM -2015 -02_E  
(DCO 3277 ) Confidential  Page 5 of 46 
 
 Protocol Summary  
Title POST -APPROVAL STUDY  of TRANSCAROTID ARTERY 
REVASCULARIZATION in PATIENTS with  SIGNIFICANT CAROTID 
ARTERY DISEASE. (The ROADSTER 2 Study ) 
Objective  
 The ROADSTER 2 Study  is intended to evaluate real world usage of the 
ENROUTE Transcarotid Stent when used with the ENROUTE Transcarotid 
Neuroprotection System by physicians of varying levels of training and 
previous experience with the transcarotid technique.  
Study Design  The ROADSTER 2 Study  is an open label, single arm, multi -center post -
approval Study  for the treatment of patients at high risk for adverse events 
from carotid endarterectomy who require carotid revascularization and who 
are eligible for treatment with a combi nation of the ENROUTE Transcarotid 
Stent System and the ENROUTE Transcarotid NPS.  
Enrollment  A minimum of 600 patients  treated per protocol . Enrollment will be an 
entirely new cohort of patients. Additional follow -up on  subjects from the 
ROADSTER IDE will  not be included.  A maximum of 30 patients per 
physician will be included in the first 600 patients.  A physician  may enroll 
more than 30 patients .   
Investigation Site  
Locations  A minimum of 30 and up to a maximum of  100 sites in the United States . A 
maximum of 5 sites in the European Union.  No more than 30% of the sites 
will be sites that previously enrolled in the ROADSTER study.  
Primary Endpoint  The rate of procedural success through 30 days following stent implant . 
Secondary 
Endpoints  The following secondary endpoints will be assessed 0 to 30 days:  
ï‚§ Acute device success  
ï‚§ Technical success  
ï‚§ Rate of cranial nerve injury  
ï‚§ Rate of c ardiac  death  
ï‚§ Rate of neurological death  
ï‚§ Rate of hierarchical ipsilateral stroke , death  and MI  
ï‚§ Rate of hierarchical ipsilateral stroke, death  and MI  by symptom status  
ï‚§ Acute device, technical and procedural success  by physician 
experience  
ï‚§ Acute device, technical and procedural success by physician trainin g 
level 
ï‚§ Acute device, technical and procedural  success by enrollment quartile  
 
Patient Population  Patients with atherosclerotic extracranial internal carotid stenosis (ICA) with 
or without involvement of the contiguous common artery (CCA) determined 
by duplex ultrasound , CT/CTA, MR/MRA  or angiography  to be:  Symptomatic 
(ï‚³ 50% stenosis ) or Asymptomatic (ï‚³ 80% stenosis ) 
Planned Schedule  Commence Enrollment : Q3 2015  
Complete Enrollment:  End of Q1 2018  
Complete 30 -day Follow -Up:    30 days following last enrollment  
Issue FDA Final Report:           Beginning of Q3 2018  
 
   
SRM -2015 -02_E  
(DCO 3277 ) Confidential  Page 23 of 46 
 
 Adjudication of Events  
 Clinical Events Committee (CEC)  
An independent Clinic al Events Committee will be assembled to review and adjudicate strokes, 
cranial nerve injuries, and UADEs (and their relationship to the device or procedure) events , as 
well as major protocol deviations  affecting patient safety , that occur while a patient is enrolled in 
the study .  The committee will be comprised of a multidisciplinary group of physicians including at 
least one neurologist , at least one vascular surgeon  and at least one cardiologist. The committee 
members will not be participating in the tr ial and will not have an affiliation with the Sponsor, 
Investigators, or Study  sites.  
 Strokes  
The CEC will adjudicate all suspected strokes.   
15.2.1  Major Stroke  
A Major Stroke  is to be defined as an increase of 5 or more in NIH Stroke Scale from baseline 
score and a Modified Rankin Score of â‰¥3. 
 
Note:  If NIH â‰¥4 at enrollment, any change â‰¥5 is considered a major stroke.  If Rankin â‰¥3 at 
enrollment, and change â‰¥1 is considered a major stroke  . 
 
15.2.2  Minor Stroke  
A Minor Stroke  is defined as an increase in NIH Stroke Scale score of  at most 4 points from 
baseline and a Modified Rankin score of at least 2.  
 
Note:  If NIH â‰¥4 at enrollment, any change â‰¤4 is considered a minor stroke  
 
 Cranial Nerve Injuries  
The CEC will adjudicate all  suspected cranial nerve injuries that occur  within 30 days  (+7 days)  of 
the procedure.  
 Statistical Methods and Determination of Sample Size   
 Overview  
The following section provides an outline of the statistical methods to be applied to the clinical 
data from this study .  A Statistical Analysis Plan, containing the details for generating the 
analyses, will be finalized prior to any analyses being conduct ed. 
16.1.1  Sample Size Calculation  
The sample size for this clinical investigation is based on the rate of procedural success within 30 
days of the stent implant.  The observed rate of procedural success in the ROADSTER 2 Study  
will be compared to an a priori  threshold of 85% derived from the ROADSTER Study.  The 
   
SRM -2015 -02_E  
(DCO 3277 ) Confidential  Page 24 of 46 
 rationale for an 85% threshold is based on the lower bound of the 2 -sided 95% exact binomial 
confidence intervals of the procedural success rates from the ROADSTER Lead -In Phase 
(91.0%, 95% CI 81.52%,  96.64%) and the ROADSTER Pivotal Phase (95.7%, 95% CI 90.97%, 
98.42%).  Given that the majority of sites that will participate in the ROADSTER 2 Study  will not 
have participated in the ROADSTER IDE, the procedural success rate must consider outcomes 
from early enrollment.  With an observed rate of procedural success >89% in the ROADSTER 2 
Study , the results will be significant with a minimum of 600 patients, meaning the lower bound of 
the 2 -sided 95% exact binomial confidence interval will exceed 85%.  Det erministically, if 534 
patients of the 600 total cases (89%) were classified as a procedural success within 30 days of 
the stent implant, the exact 95% lower binomial confidence limit would be 86.22%.  
Estimates for the 3 categories of physician level of training and experience (yes/no) will be 
summarized.  However, given the distribution of physicians by level of training and experience will 
not be controlled for in this clinical investigation, it is indeterminate how informative the estimates 
will be. 
 Endpoint Analyses and Hypothesis Testing  
The hypothesis testing will be focused on the proportion of patients classified as a procedural 
success, and to examine differences among the levels of physician training and the experience  of 
physicians .  
16.2.1  Primary Endpoint  
The primary endpoint for the study is the rate of procedural success through 30 days following 
stent implant.  The derivation of the endpoint for the primary analysis of the primary endpoint will 
consider all patients who undergo the procedu re and in the absence of a major protocol deviation , 
i.e., the Per Protocol population.  Patients who exit the study prior to the 30 day post -procedure 
evaluation who meet the definition of a procedural success based on their last observation will be 
count ed in the analysis as a procedural success.  Secondary analyses of the primary endpoint 
will consider alternative methods of imputation; the details of these supplemental analyses will be 
described in the Statistical Analysis Plan.    
16.2.2  Primary Analysis of t he Primary Endpoint  
The dependent variable used in the primary analysis will be dichotomous and set to Yes if the 
patient is a procedural success through 30 days following stent implant  and No if they are not a 
procedural success through 30 days following stent implant .  Results from the analysis of the 
primary endpoint will be based on a 2 -sided binomial test, compared to an a priori  threshold of 
85.0%.  The 2 -sided 95% exact binomial confidence intervals will also be presented.  Patients 
who withdraw prio r to 30 days, but at the time of withdraw were tracking to meet the definition of a 
procedural success, will be counted in the analysis as a procedural success.   
16.2.3  Secondary Endpoint  
The analyses to be conducted on the secondary endpoints are intended to pr ovide additional 
supportive evidence of the efficacy and safety of the device.  There are 10 secondary endpoints 
that will be assessed at 30 days post -procedure; each of the secondary endpoints is a 
dichotomous variable:  
ï‚· Acute device success  
ï‚· Technical succ ess 
ï‚· Rate of cranial nerve injury  
   
SRM -2015 -02_E  
(DCO 3277 ) Confidential  Page 25 of 46 
 ï‚· Rate of cardiac  death  
ï‚· Rate of neurological death  
ï‚· Rate of hierarchical ipsilateral stroke, death and MI  
ï‚· Rate of hierarchical ipsilateral stroke, death and MI by symptom status  
ï‚· Acute device, technical and procedural success by physician experience  
ï‚· Acute device, technical and procedural success by physician training level  
ï‚· Acute device, technical and procedural success by enrollment quartile  
 Statistical Methods  
The pre -procedure observations will serve as the baseline  values fo r calculating post procedure 
changes from baseline.  Tabulations of summary statistics, graphical presentations, and statistical 
analyses will be performed using SAS software version 9.2 or higher.  The statistical analyses will 
be based on data pooled acr oss Sites  in aggregate ; a secondary tabulation will be prepared 
separately for the US and Non -US sites .  Continuous demographic parameters, such as the age 
of the patient at the time of enrollment, will be summarized for the Per -Protocol population using 
descriptive statistics (N, mean, median, standard deviation, minimum and maximum value, and 
95% 2 -sided confidence limits).  Continuous demographic parameters will be compared among 
the 3 levels of physician training and experience using a 1 -factor (physici an training  [1, 2 or 3] ; 
physician experience [participation in ROADSTER 1 or no participation in ROADSTER 1 ) analysis 
of variance model.  Contrast statements will be used to evaluate the individual pair wise 
comparisons (Level 1 vs. Level 2, Level 1 vs. L evel 3, and Level 2 vs. Level 3 ; participation in 
ROADSTER 1 vs no participation in ROADSTER 1 ).  Categorical demographic parameters, such 
as gender, will be summarized as a proportion of the Per -Protocol population using Clopper -
Pearson 95% 2 -sided confid ence limits.  The categorical demographic parameters will be 
compared using a Mantel -Haenszel test stratified on physician level of training (1, 2, or 3) and 
separately by physician experience  (participation in ROADSTER 1 vs no participation in 
ROADSTER 1) .  Additionally, a generalized linear model (PROC GENMOD) will be used to 
evaluate the main effect of physician level of experience, specifying the distribution as either 
binomial or multinomial.  Clinical and high risk factors will also be summarized as a  proportion of 
the Per -Protocol population with Clopper -Pearson 95% 2 -sided confidence limits.  In addition to 
the overall summary of the individual factors, separate summaries will be generated by physician 
experience  and level of training .  Comparisons w ill be made among the 3 levels of physician 
training and physician experience  (participation in ROADSTER 1 vs no participation in 
ROADSTER 1) , depending on the type and distribution of the parameter.  
 
Data obtained during the neurological examination, including data from the NIH Stroke Scale, 
Modified Rankin Scale and Cranial Nerve Palsy Assessment will be summarized at each time 
point using descriptive statistics.  Separate summaries will be generated by level of physician 
training and experience and compared using a 1 -factor (physician level of training  [1, 2 or 3] ) and 
a 1-factor (experience: participation in ROADSTER 1 vs. no participation in ROADSTER 1 ) 
analysis of variance model.  Contrast statements will be used to evaluate the individual pair wise 
comparisons (Level 1 vs. Level 2, Level 1 vs. Level 3, and Level 2 vs. Level 3).    
 
Specific algorithms for imputing missing or partially missing dates wi ll be discussed in the SAP.  
Derived data will be identified in the individual patient data listings.  Imputed data for dates will not 
   
SRM -2015 -02_E  
(DCO 3277 ) Confidential  Page 26 of 46 
 be incorporated into the case report form datasets.  Imputed data for dates will be used in the 
preparation of the derive d datasets.  
 Populations for Analysis  
The Per -Protocol population is defined as p atients who sign an informed consent, undergo the 
study procedure, independent of the success of the procedure, and with the absence of major 
protocol deviations .  Patients who  sign an informed consent, however fail to undergo the study 
procedure, will not be included in the Per -Protocol population. A maximum of 30 patients treated 
per protocol per physician can contribute to the 600 patient minimum.  A physician may enroll 
more  than 30 patients.  
 
The primary endpoint and all secondary endpoints will be analyzed based on the Per -protocol 
population.  All available data on the Per-Protocol patients who enrolled in the study will be 
included.   Any subject not meeting the Inclusion/ Exclusion criteria will be tabulated but not 
included in the primary endpoint analysis.  
 
 Data Collection  
Data will be entered into a validated electronic data management system.  Data fields in the 
selected electronic data management system used will be aligned such that it overlaps with the 
appropriate data fields for the post -approval study as derived from the ROADSTER IDE.  
 Sponsor Responsibilities  
 Selection of Clinical Investigators and Sites  
All US sites p articipat ing in the ROADSTER 2 Study  will be l imited to institutions with current 
CMS carotid stent certification.  Institutions will be compensated for complete and accurate data 
collection.  
 Training of Investigators and Site Personnel  
Investigators and site personnel will be trained on the followin g aspects of the clinical study:  
ï‚Ÿ Protocol  
ï‚Ÿ Case Report Forms  
ï‚Ÿ Risks and Benefits  
ï‚Ÿ Reporting Responsibilities  
ï‚Ÿ Informed Consent  
ï‚Ÿ Device Usage  
ï‚Ÿ Device Instructions for Use  
ï‚Ÿ Confidentiality  
Investigator responsibilities are further detailed below.  